Sunday 18 October 2026
Export CYTT’s income statement to Excel — free account
Cyteir Therapeutics, Inc.
CYTT Healthcare Biotechnology
Dividend growth for five consecutive years.
3.01
0.00
0.00%
Follow CYTT
| Older periods | Dec '22 | Mar '23 | Jun '23 | Sep '23 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(27.62%) | (28.72%) | (27.94%) | (23.80%) | |
| (26.42%) | (27.36%) | (26.38%) | (22.70%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(31.64%) | (32.98%) | (31.93%) | (26.62%) | |
Average Days of Receivables |
— | 0.00 | 0.00 | — | |
Free Cash Flow per Share |
(1.21) | (1.14) | (0.94) | (0.71) | |
Free Cash Flow |
(42.84) | (40.50) | (33.51) | (25.49) | |
Capital Expenditures |
(0.31) | 0.03 | 0.29 | 0.30 | |
| Other line items | |||||
Cash ROIC |
(14.60%) | (14.88%) | (12.82%) | (10.02%) | |
Accounts Payable Turnover |
0.61 | 0.49 | 0.38 | 0.77 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
465.22 | 237.92 | 523.27 | 222.33 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(22.84) | (13.10) | (9.50) | (6.78) | |
Operating CF/Net income |
0.92 | 0.91 | 0.83 | 0.78 | |
Depreciation/Fixed assets |
0.39 | 2.04 | 2.78 | 5.12 | |
Capex/Depreciation |
(0.47) | 0.04 | 0.49 | 0.56 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.21) | (1.14) | (0.95) | (0.72) | |
Capex per Share |
(0.01) | 0.00 | 0.01 | 0.01 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates